Literature DB >> 21394820

Benefit-incidence analysis: are government health expenditures more pro-rich than we think?

Adam Wagstaff1.   

Abstract

Authors of benefit-incidence analyses (BIA) have to impute subsidies using assumptions about the relationship between unobserved subsidies 'captured' by the household and what can be observed at the household and aggregate levels. This paper shows that one of the two assumptions used in BIA studies to date will necessarily produce a more pro-rich (or less pro-poor) picture of government health spending than the other, depending on whether utilization is more pro-rich or pro-poor than fees paid to public providers. Both assumptions have their disadvantages, and the paper suggests a couple of alternatives that explicitly link fees paid to the costliness of care. It shows that in the most likely case where fees are distributed in a more pro-rich fashion than utilization, the two traditional assumptions will produce less pro-rich distributions of subsidies than the two new alternatives. Also considered are three complications that arise in BIA studies, including factoring in social health insurance. The paper's theoretical results are illustrated with an empirical BIA for Vietnam.
Copyright © 2011 John Wiley & Sons, Ltd.

Mesh:

Year:  2011        PMID: 21394820     DOI: 10.1002/hec.1727

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  23 in total

1.  Inequity in hospitalization care: a study on utilization of healthcare services in West Bengal, India.

Authors:  Montu Bose; Arijita Dutta
Journal:  Int J Health Policy Manag       Date:  2014-12-22

2.  Equity in public health spending in Ethiopia: a benefit incidence analysis.

Authors:  Alemayehu Hailu; Roman Gebreyes; Ole F Norheim
Journal:  Health Policy Plan       Date:  2021-11-12       Impact factor: 3.547

3.  Assessment of equity in healthcare financing in Fiji and Timor-Leste: a study protocol.

Authors:  Augustine D Asante; Jennifer Price; Andrew Hayen; Wayne Irava; Joao Martins; Lorna Guinness; John E Ataguba; Supon Limwattananon; Anne Mills; Stephen Jan; Virginia Wiseman
Journal:  BMJ Open       Date:  2014-12-02       Impact factor: 2.692

4.  Has equity in government subsidy on healthcare improved in China? Evidence from the China's National Health Services Survey.

Authors:  Lei Si; Mingsheng Chen; Andrew J Palmer
Journal:  Int J Equity Health       Date:  2017-01-10

5.  System-wide analysis of health financing equity in Cambodia: a study protocol.

Authors:  Virginia Wiseman; Augustine Asante; Por Ir; Supon Limwattananon; Bart Jacobs; Marco Liverani; Andrew Hayen; Stephen Jan
Journal:  BMJ Glob Health       Date:  2017-01-03

6.  Health insurance benefit design and healthcare utilization in northern rural China.

Authors:  Hong Wang; Yu Liu; Yan Zhu; Lei Xue; Martha Dale; Heather Sipsma; Elizabeth Bradley
Journal:  PLoS One       Date:  2012-11-21       Impact factor: 3.240

Review 7.  Equity in Health Care Financing in Low- and Middle-Income Countries: A Systematic Review of Evidence from Studies Using Benefit and Financing Incidence Analyses.

Authors:  Augustine Asante; Jennifer Price; Andrew Hayen; Stephen Jan; Virginia Wiseman
Journal:  PLoS One       Date:  2016-04-11       Impact factor: 3.240

8.  Assessing equity in benefit distribution of government health subsidy in 2012 across East China: benefit incidence analysis.

Authors:  Mingsheng Chen; Andrew J Palmer; Lei Si
Journal:  Int J Equity Health       Date:  2016-01-20

9.  Who benefited from the New Rural Cooperative Medical System in China? A case study on Anhui Province.

Authors:  Lidan Wang; Anjue Wang; Gerry FitzGerald; Lei Si; Qicheng Jiang; Dongqing Ye
Journal:  BMC Health Serv Res       Date:  2016-06-05       Impact factor: 2.655

10.  How to do (or not to do) … a health financing incidence analysis.

Authors:  John E Ataguba; Augustine D Asante; Supon Limwattananon; Virginia Wiseman
Journal:  Health Policy Plan       Date:  2018-04-01       Impact factor: 3.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.